In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will get treatment till disorder progression or maybe the members are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit merchandise within three times before the https://albertz211kvf3.izrablog.com/profile